Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (167)

Search Parameters:
Keywords = round cell tumor

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
14 pages, 1925 KiB  
Article
Chitosan Microparticles Coupled with MAGE-AX and CpGs as a Treatment for Murine Melanoma
by Gabriela Piñón-Zárate, Beatriz Hernández-Téllez, Ariel Ramírez-Cortés, Katia Jarquín-Yáñez, Enrique A. Sampedro-Carrillo, Miguel A. Herrera-Enríquez, Christian A. Cárdenas-Monroy and Andrés E. Castell-Rodríguez
Pharmaceutics 2025, 17(7), 932; https://doi.org/10.3390/pharmaceutics17070932 - 19 Jul 2025
Viewed by 324
Abstract
Background/Objectives: One current cancer treatment is immunotherapy, in which tumor antigens (such as MAGE) or adjuvants (such as CpGs) can be used to induce the destruction of tumor cells by the immune system; however, the therapeutic response is generally weak. Therefore, it is [...] Read more.
Background/Objectives: One current cancer treatment is immunotherapy, in which tumor antigens (such as MAGE) or adjuvants (such as CpGs) can be used to induce the destruction of tumor cells by the immune system; however, the therapeutic response is generally weak. Therefore, it is necessary to develop a strategy that increases the immune response induced by tumor antigens and CpGs. We propose the coupling of tumor antigens and adjuvants to chitosan (Cs) microparticles to improve the immune response against cancer, as these microparticles can activate the innate immune response when recognized by macrophages and dendritic cells (DCs). Methods: Cs microparticles coupled with CpGs and tumor antigens were constructed with the emulsification method; then, their morphology, in vitro biological effect on DCs, and therapeutic effect in a murine melanoma model were analyzed. Results: The Cs microparticles showed a rounded morphology and a size of approximately 5 μ; in addition, they were not cytotoxic in in vitro assays and induced the production of IFNα. Finally, in the murine model of melanoma, treatment with Cs microparticles coupled to MAGE or CpGs reduced the tumor growth rate and increased both survival and the presence of cell death areas in the tumor parenchyma in contrast to the control group. Conclusions: The results suggest that treatment with Cs microparticles coupled to tumor antigen and/or CpGs can be considered a promising strategy in the field of immunotherapy based on the use of biomaterials. Full article
Show Figures

Graphical abstract

15 pages, 1405 KiB  
Article
Risk Factors for the Occurrence of Cutaneous Neoplasms in Dogs: A Retrospective Study by Cytology Reports, 2019–2021
by Issa Carolina García-Reynoso, Cesar Augusto Flores-Dueñas, Nohemí Castro-del Campo, Mariana Jácome-Ibarra, José Carlomán Herrera-Ramírez, Sergio Daniel Gómez-Gómez, Miguel Ángel Rodríguez-Gaxiola and Soila Maribel Gaxiola-Camacho
Animals 2025, 15(14), 2069; https://doi.org/10.3390/ani15142069 - 14 Jul 2025
Viewed by 384
Abstract
Studies worldwide report cutaneous neoplasms in dogs; however, data in the arid regions of Mexico remain scarce. Here we report the main malignant cutaneous neoplasms diagnosed by fine needle aspiration cytology (FNAC), and describe the associations with age, sex and breed in Mexicali. [...] Read more.
Studies worldwide report cutaneous neoplasms in dogs; however, data in the arid regions of Mexico remain scarce. Here we report the main malignant cutaneous neoplasms diagnosed by fine needle aspiration cytology (FNAC), and describe the associations with age, sex and breed in Mexicali. Neoplastic lesions accounted for 25.52% (698/2735) of the cases, of which 56.59% (395/698) were malignant. The highest prevalence was observed in dogs aged 9–12 years (n = 193), intact males (n = 162), and mixed-breed dogs (n = 247). Round cell neoplasms (n = 309), including lymphoma, transmissible venereal tumors (TVT), and mast cell tumors (MCT), were the most common cell lineage. Using dogs aged 0–4 years as the reference group, dogs aged 9–12 years had 0.241 times the odds of developing malignant neoplasms (95% CI: 0.141–0.415, p = 0.0025). Using neutered males as the reference group, intact females showed 2.499 times the odds of developing malignant neoplasms (95% CI: 1.462–4.271, p = 0.0042). Compared to mixed-breed dogs, Schnauzers (OR = 0.161) showed significantly lower odds of malignancy (95% CI: 0.082–0.317, p = 0.0004), while Pitbull Terriers had 1.748 times more chance of present malignant neoplasia (95% CI: 1.014–3.013, p < 0.0001). This study provides significant epidemiological evidence on canine cutaneous neoplasms in an arid region of Mexico, identifying key risk factors and distribution patterns that can guide preventive, diagnostic, and therapeutic strategies tailored to regional characteristics. Full article
(This article belongs to the Special Issue Advances in Animal Clinical Pathology)
Show Figures

Figure 1

18 pages, 8645 KiB  
Article
CIC-Rearranged Sarcoma: A Clinical and Pathological Study of a Peculiar Entity
by Ward Maaita, Nabil Hasasna, Sameer Yaser, Yacob Saleh, Ramiz Abu-Hijlih, Wafa Asha, Hadeel Halalsheh, Samer Abdel Al, Maysa Al-Hussaini and Omar Jaber
Diagnostics 2025, 15(14), 1758; https://doi.org/10.3390/diagnostics15141758 - 11 Jul 2025
Viewed by 424
Abstract
Background: CIC-rearranged sarcoma is a rare and aggressive type of undifferentiated round cell tumor characterized by CIC gene fusion, most commonly CIC::DUX4. This study presents a series of eleven cases, highlighting their clinicopathological features. Methods: Pathology records (2019 to 2024) [...] Read more.
Background: CIC-rearranged sarcoma is a rare and aggressive type of undifferentiated round cell tumor characterized by CIC gene fusion, most commonly CIC::DUX4. This study presents a series of eleven cases, highlighting their clinicopathological features. Methods: Pathology records (2019 to 2024) were searched using “sarcoma with CIC”, identifying eleven cases, of which seven referred cases were initially misdiagnosed. Pathological and clinical analysis was conducted. Treatment was dictated upon multidisciplinary panel discussion based on tumor stage. Follow-up data (1–25 months) was available for all patients. Results: The cohort included six males and five females, with a median age of 43 years (range;14–53), with nine in soft tissue and two in bone. Tumor size ranged from 3.5 cm to 20.0 cm (mean: 9.8 cm). Most cases showed sheets of undifferentiated round- to oval-shaped cells. Two cases showed an Ewing-like pattern, and one case showed spindle cells in a fibrotic stroma transitioning to epithelioid cells. Necrosis was present in nine cases, and mitotic count ranged from 2 to 38/ 10HPFs (mean = 14.2). CD99 was positive in (10/11) cases and WT-1 in (6/9). NKX2.2, S100, and MDM2 were positive in rare cases. CIC::DUX4 fusion was detected in four cases. FISH for CIC gene rearrangement was positive in seven cases, two of them confirmed by methylation analysis. Metastasis at diagnosis was common (n = 8), primarily in the lungs, with later metastasis to the brain and bone. At time of final analysis, eight patients died within a median of 10 months (range: 1–19 months), while three were alive, two with stable disease (for a period of 6 and 25 months) and one with progression after 10 months. Significant correlation was seen between overall survival and the presence of metastasis at diagnosis (p value = 0.03). Conclusions: CIC-rearranged sarcomas are rare, high-grade tumors with predilection for soft tissue. Misdiagnosis is frequent, necessitating molecular confirmation. These tumors are treatment-resistant, often present with lung metastasis, and carry a poor prognosis, especially with initial metastasis. Full article
(This article belongs to the Section Pathology and Molecular Diagnostics)
Show Figures

Figure 1

17 pages, 2500 KiB  
Article
Superhydrophobicity Effects on Spheroid Formation, Structure, and Viability on Co-Culture Conditions
by María del Carmen Morán, Francesca Cirisano and Michele Ferrari
Pharmaceuticals 2025, 18(7), 953; https://doi.org/10.3390/ph18070953 - 24 Jun 2025
Viewed by 336
Abstract
Background/Objectives: Three-dimensional (3D) cell culture models more accurately simulate the in vivo tissue environments as compared to conventional two-dimensional (2D) monolayer cultures. Among these, spheroid cultures are particularly valuable for pharmaceutical research, as they allow for the study of tumor growth, drug responses, [...] Read more.
Background/Objectives: Three-dimensional (3D) cell culture models more accurately simulate the in vivo tissue environments as compared to conventional two-dimensional (2D) monolayer cultures. Among these, spheroid cultures are particularly valuable for pharmaceutical research, as they allow for the study of tumor growth, drug responses, and cell–cell interactions in a physiologically relevant manner. Superhydrophobic surfaces (SHSs) have shown a promise in enhancing spheroid formation by reducing cell–substrate adhesion and promoting cell–cell aggregation. This study aims to evaluate the effectiveness of two different SHS coatings (SHS1: fluorinated; SHS2: silicone-based) in generating co-culture spheroids composed of non-tumoral fibroblasts (3T3) and tumoral epidermoid carcinoma cells (A431), thereby mimicking aspects of the tumor microenvironment. Methods: Co-cultures of 3T3 and A431 cells were seeded at varying ratios onto SHS1 and SHS2 substrates to assess their ability to support 3D spheroid formation. Spheroids were characterized by measurements of circularity and size distribution, viability through live/dead staining, and surface topography using 3D profilometry. Results: Spheroid formation was significantly influenced by both the surface properties and the fibroblast-to-carcinoma cell ratio. The fluorinated SHS1 surface facilitated superior cell viability and promoted the formation of well-rounded, uniform spheroids. In contrast, the silicone-based SHS2 surface resulted in less defined spheroidal structures and lower overall viability. Profilometry confirmed more consistent and compact 3D architectures on SHS1. Conclusions: This study demonstrates that SHS1, a fluorinated superhydrophobic coating, is more effective than SHS2 in supporting the formation of viable and structurally coherent 3D co-culture spheroids. These findings underscore the potential of SHS1 as a low-cost, tunable platform for developing in vitro cancer models and advancing the study of tumor–stroma interactions. Full article
(This article belongs to the Section Pharmaceutical Technology)
Show Figures

Graphical abstract

14 pages, 5450 KiB  
Case Report
Extramedullary Relapse of CBFA2T3::GLIS2-Positive Megakaryoblastic Leukemia Mimicking Secondary Ewing Sarcoma: An Exemplary Case for the Diagnostic Trap
by Svetlana Lebedeva, Ekaterina Mikhailova, Sophia Bogacheva, Dmitry Abramov, Svetlana Kashpor, Alexander Druy, Alexandra Semchenkova, Marina Gaskova, Olga Lotonina, Ilya Sidorov, Galina Tereschenko, Yulia Olshanskaya, Galina Novichkova, Alexey Maschan, Elena Zerkalenkova and Alexander Popov
Int. J. Mol. Sci. 2025, 26(12), 5895; https://doi.org/10.3390/ijms26125895 - 19 Jun 2025
Viewed by 478
Abstract
In children without Down syndrome who have acute megakaryoblastic leukemia (AMKL), inv(16)(p13q24)/CBFA2T3::GLIS2 is the most frequent genetic aberration. Pediatric CBFA2T3::GLIS2-positive AMKL is strongly associated with a poor prognosis and a high cumulative incidence of relapse. One of the key laboratory signs [...] Read more.
In children without Down syndrome who have acute megakaryoblastic leukemia (AMKL), inv(16)(p13q24)/CBFA2T3::GLIS2 is the most frequent genetic aberration. Pediatric CBFA2T3::GLIS2-positive AMKL is strongly associated with a poor prognosis and a high cumulative incidence of relapse. One of the key laboratory signs of CBFA2T3::GLIS2-positive AMKL is the RAM immunophenotype, which looks very similar to that of solid-tumor bone marrow (BM) infiltration. For this reason, in cases of isolated extramedullary involvement of CBFA2T3::GLIS2-positive AMKL, excluding solid tumors may be challenging. We report a case of a girl with isolated extramedullary CBFA2T3::GLIS2-positive AMKL relapse, which was misdiagnosed as secondary Ewing sarcoma. The morphological differential diagnosis between Ewing sarcoma and AMKL presented significant challenges owing to their overlapping histological features (small, round blue-cell morphology and similar growth patterns). The tumor cells’ immunophenotype completely mirrored that at the initial diagnosis of AMKL. Additional cytogenetic and molecular studies confirmed the presence of the CBFA2T3::GLIS2 fusion, but no Ewing sarcoma-specific EWSR1, FUS and CIC fusion transcripts were found. Thus, extramedullary CBFA2T3::GLIS2-positive AMKL relapse was confirmed. The presented case demonstrates the difficulties in differential diagnosis between AMKL relapse and the development of a secondary tumor. Full article
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Show Figures

Figure 1

13 pages, 277 KiB  
Systematic Review
Evaluation of Prognostic Factors in Myxoid Liposarcoma Treated with Combined Neoadjuvant Radiotherapy and Surgical Excision: Systematic Review
by Giuseppe Francesco Papalia, Giulia De Marco, Claudia Luciano, Luisana Sisca, Pasquale Farsetti, Bruno Vincenzi and Rocco Papalia
Diseases 2025, 13(6), 177; https://doi.org/10.3390/diseases13060177 - 6 Jun 2025
Viewed by 388
Abstract
Purpose: Myxoid liposarcoma (MLPS) is a malignant tumor that occurs predominantly in the deep soft tissues of the extremities. Preoperative radiotherapy (RT) is used to reduce tumor volume to achieve adequate surgical margins. This systematic review aims to evaluate the impact of preoperative [...] Read more.
Purpose: Myxoid liposarcoma (MLPS) is a malignant tumor that occurs predominantly in the deep soft tissues of the extremities. Preoperative radiotherapy (RT) is used to reduce tumor volume to achieve adequate surgical margins. This systematic review aims to evaluate the impact of preoperative RT on surgical margins, local recurrence (LR) rates, metastasis development, and overall survival in patients with MLPS and associated prognostic factors. Methods: A systematic literature search was conducted by two reviewers following PRISMA guidelines on PubMed, Scopus, and the Cochrane Library on 30 November 2024. We included prospective and retrospective cohort studies published in English that evaluate surgical margin status, LR and metastasis rates, and survival outcomes in patients undergoing surgical excision of MLPS following neoadjuvant radiotherapy. Two authors extracted tumor characteristics, percentage of round cells (RCs), change in tumor volume post-RT, surgical margins, postoperative complications, LR and metastasis rates, survival rates, and related prognostic factors. Results: The twelve studies included in this review involved 1483 patients with a mean age of 44.8 years. Tumors were mostly located in the lower limbs, deeply localized, and larger than 5 cm in most cases. The average LR and metastasis rates were 5.2% and 17%, respectively. The mean 5-year and 10-year overall survival rates were 87% and 74%, respectively. Poor prognosis was associated with >5% RC components, tumors larger than 15 cm, deep localization, and inadequate surgical margins. Conclusion: The management of MLPS requires a multidisciplinary approach. Preoperative radiotherapy offers several advantages in reducing tumor volume and facilitating the achievement of adequate surgical margins, finally improving local control and long-term outcomes. Full article
Show Figures

Figure 1

15 pages, 1285 KiB  
Article
Canine Transmissible Venereal Tumor: Anatomical Locations, Chemotherapy Response, and Epidemiological Aspects at a Veterinary Teaching Hospital in Brazil (2012–2022)
by Pedro Antônio Bronhara Pimentel, Lorena Diniz Macedo Silva Maia, Isadora Maria Sátiro de Oliveira, Camila Stefanie Fonseca de Oliveira, Antonio Giuliano, Angel Almendros and Rodrigo dos Santos Horta
Animals 2025, 15(12), 1675; https://doi.org/10.3390/ani15121675 - 6 Jun 2025
Viewed by 1208
Abstract
Canine transmissible venereal tumor (CTVT) is a contagious neoplasm with low metastatic potential, primarily affecting free-roaming and stray dogs. Despite its global presence, epidemiological data from some regions remain limited. This study employed a retrospective observational design and analyzed 131 CTVT cases diagnosed [...] Read more.
Canine transmissible venereal tumor (CTVT) is a contagious neoplasm with low metastatic potential, primarily affecting free-roaming and stray dogs. Despite its global presence, epidemiological data from some regions remain limited. This study employed a retrospective observational design and analyzed 131 CTVT cases diagnosed via cytology or histopathology at a veterinary teaching hospital in Belo Horizonte, Brazil, aiming to describe the anatomical distribution, treatment outcomes, and epidemiological patterns. Most affected dogs were mixed-breed (70.2%) and female (61.1%), with a median age of 4.5 years. Genital involvement was most common (87.0%), followed by cutaneous (10.7%), nasal (6.1%), and oral (4.6%) tumors. Concurrent tumor locations included genital-cutaneous (5.3%) and oronasal (3.1%). Females had more genital cases, while males were more likely to present cutaneous and nasal CTVT, with 5.2 times greater odds for nasal tumors (OR = 5.2; 95% CI = 1.2–25.9). Purebred dogs also had increased odds of nasal involvement (OR = 8.2; 95% CI = 1.9–40.7). Vincristine chemotherapy was effective, and the number of sessions required for a complete response was not associated with clinical presentation, breed or size. These findings highlight the varied presentations of CTVT and reinforce the need for clinical awareness of non-genital forms. Full article
(This article belongs to the Section Companion Animals)
Show Figures

Graphical abstract

16 pages, 2112 KiB  
Article
Beyond Individual Acute Phase Protein Assessments: Introducing the Acute Phase Index (API) as a Prognostic Indicator in Dogs with Malignant Neoplasia
by Martina Baldin, Maria Elena Gelain, Giacomo Marolato, Silvia Bedin, Michele Berlanda, Manuela Zanetti, Filippo Torrigiani, Alessia Giordano, Pierangelo Moretti, Donatella Scavone and Federico Bonsembiante
Vet. Sci. 2025, 12(6), 533; https://doi.org/10.3390/vetsci12060533 - 1 Jun 2025
Viewed by 1048
Abstract
Acute phase proteins (APPs) are part of the innate immune response, changing during inflammation. An Acute Phase Index (API) is a calculated value that combines multiple APPs. In human medicine, the introduction of APIs has improved outcome monitoring. In veterinary medicine, APIs have [...] Read more.
Acute phase proteins (APPs) are part of the innate immune response, changing during inflammation. An Acute Phase Index (API) is a calculated value that combines multiple APPs. In human medicine, the introduction of APIs has improved outcome monitoring. In veterinary medicine, APIs have been evaluated in livestock and dogs with Leishmaniasis. This study aimed to calculate an API and evaluate its significance in cancer-bearing dogs. Sera were collected from 55 dogs, which were classified by neoplastic category and survival times (> or < than 30 and 90 days). For 32 dogs, multiple samples were available. The API included C-Reactive Protein (CRP) and haptoglobin as positive APPs, and albumin and Paraoxonase-1 (PON-1) as negative APPs. An alternative API excluding PON-1 was calculated. PON-1 levels were lower in round-cell tumors, suggesting increased oxidative stress. Moreover, API increased and PON-1 activity decreased in the last sample in dogs that died before the end of the study. Dogs with shorter survival times showed increased APIs and CRP levels. APIs with and without PON-1 greater than 0.049 and 0.202 at the first sampling were associated with a 3.7- and 4.4-fold higher probability of death, respectively. These results suggest a potential prognostic value of API in dogs with neoplasia. Full article
(This article belongs to the Section Veterinary Internal Medicine)
Show Figures

Figure 1

15 pages, 5384 KiB  
Article
Clinical Differences Among Histological Categories of Sarcoma: Insights from 97,062 Patients
by Yiqun Han, Ahmed Shah, Yuan Yao, Robert W. Mutter and Meng Xu-Welliver
Cancers 2025, 17(10), 1706; https://doi.org/10.3390/cancers17101706 - 20 May 2025
Viewed by 614
Abstract
Objectives: To evaluate the clinical heterogeneity of sarcomas by examining associations between histological subtypes, metastatic patterns, treatment modalities, and survival outcomes. Methods: We analyzed data from 97,062 adult patients diagnosed with sarcoma between 2000 and 2020, using the Surveillance, Epidemiology, and End Results [...] Read more.
Objectives: To evaluate the clinical heterogeneity of sarcomas by examining associations between histological subtypes, metastatic patterns, treatment modalities, and survival outcomes. Methods: We analyzed data from 97,062 adult patients diagnosed with sarcoma between 2000 and 2020, using the Surveillance, Epidemiology, and End Results (SEER) database. Fourteen histological subtypes were included. Propensity score matching (PSM) was employed to adjust for baseline differences, and Cox proportional hazards models were used to identify prognostic variables. Results: The most prevalent subtypes were sarcoma not otherwise specified (31.9%), leiomyosarcoma (17.1%), and liposarcoma (13.9%). Metastatic patterns differed significantly by subtype; liver metastases were most common in sarcomas with small blue round cell (SBRC) features (8.9%) and stromal sarcoma (6.1%), while lung metastases were frequently observed in Ewing sarcoma (10.0%) and rhabdomyosarcoma (9.7%). Median overall survival (mOS) varied widely, ranging from 234 months in chondrosarcoma to 16–20 months in rhabdomyosarcoma and SBRC sarcoma. Overall, patients with primary sarcoma had significantly better survival than those with treatment-related disease (119.0 vs. 45.0 months, p < 0.0001), with this trend consistent across most subtypes. Treatment responses were subtype- and size-dependent. For instance, surgery plus radiotherapy improved outcomes in giant cell sarcoma regardless of tumor size, whereas chemotherapy provided benefit only in tumors larger than 5 cm. Combined surgery and radiotherapy offered additional survival benefit in select subtypes, including chordoma, leiomyosarcoma (>5 cm), and synovial sarcoma (<5 cm). Conclusions: Sarcomas exhibit substantial clinical and prognostic heterogeneity across histological subtypes. These findings underscore the importance of subtype-specific, individualized treatment strategies in optimizing patient outcomes. Full article
Show Figures

Figure 1

18 pages, 3150 KiB  
Article
Targeting ATF5, CEBPB, and CEBPD with Cell-Penetrating Dpep Sensitizes Tumor Cells to NK-92MI Cell Cytotoxicity
by Qing Zhou, Markus D. Siegelin and Lloyd A. Greene
Cells 2025, 14(9), 667; https://doi.org/10.3390/cells14090667 - 2 May 2025
Viewed by 615
Abstract
Natural killer (NK) cells are an important innate defense against malignancies, and exogenous sources of NK cells have been developed as anti-cancer agents. Nevertheless, the apparent limitations of NK cells in clearing cancers have suggested that their efficacy might be augmented by combination [...] Read more.
Natural killer (NK) cells are an important innate defense against malignancies, and exogenous sources of NK cells have been developed as anti-cancer agents. Nevertheless, the apparent limitations of NK cells in clearing cancers have suggested that their efficacy might be augmented by combination with other treatments. We have developed cell-penetrating peptides that target the transcription factors ATF5, CEBPB, and CEBPD and that promote apoptotic cancer cell death both in vitro and in vivo without apparent toxicity to non-transformed cells. We report here that one such peptide, Dpep, significantly sensitizes a variety of tumor cell types to the cytotoxic activity of the NK cell line, NK-92MI. Such sensitization requires pre-exposure of tumor cells to Dpep and does not appear due to effects of Dpep on NK cells themselves. Our findings suggest that Dpep acts in this context to lower the apoptotic threshold of tumor cells to NK cell toxicity. Additionally, while Dpep pre-treatment does not prevent tumor cells from causing NK cell “inactivation”, it sensitizes cancer cells to repeated rounds of exposure to fresh NK cells. These findings thus indicate that Dpep pre-treatment is an effective strategy to sensitize cancer cells to the cytotoxic actions of NK cells. Full article
Show Figures

Figure 1

33 pages, 4263 KiB  
Review
Iatrogenic Ocular Surface Complications After Surgery for Ocular and Adnexal Tumors
by Maria Angela Romeo, Andrea Taloni, Massimiliano Borselli, Alessandra Di Maria, Alessandra Mancini, Vincenzo Mollace, Giovanna Carnovale-Scalzo, Vincenzo Scorcia and Giuseppe Giannaccare
Cancers 2025, 17(9), 1384; https://doi.org/10.3390/cancers17091384 - 22 Apr 2025
Viewed by 1243
Abstract
Background/Objectives: The management of ocular tumors often necessitates surgery, either alone or in combination with radiotherapy, chemotherapy, or other modalities. While crucial for tumor control, these treatments can significantly impact the ocular surface, leading to both acute and chronic complications. This review examines [...] Read more.
Background/Objectives: The management of ocular tumors often necessitates surgery, either alone or in combination with radiotherapy, chemotherapy, or other modalities. While crucial for tumor control, these treatments can significantly impact the ocular surface, leading to both acute and chronic complications. This review examines iatrogenic ocular surface diseases resulting from oncologic interventions, emphasizing their pathophysiology, diagnostic challenges, and management strategies. Methods: A literature review was conducted to identify studies on iatrogenic ocular surface complications associated with ocular tumor treatments. Results: Ocular surface complications include direct damage from surgical manipulation, leading to corneal opacities and persistent epithelial defects, as well as dry eye disease secondary to postoperative chemosis. These disruptions may progress to more severe conditions such as keratopathy, corneal ulcers, limbal stem cell deficiency, and stromal scarring, further impairing visual function. Structural alterations contribute to eyelid malpositions—including ectropion, entropion, round eye, and lagophthalmos—which exacerbate exposure-related damage and ocular surface instability. In cases of uveal melanomas, the exposure of episcleral brachytherapy plaques can induce chronic conjunctival irritation, promoting adhesion formation and symblepharon. Surgical interventions disrupt ocular surface homeostasis, while radiotherapy and chemotherapy exacerbate these effects through cytotoxic and inflammatory mechanisms. Conclusions: Preventing and managing iatrogenic ocular surface complications require a multidisciplinary approach involving early diagnosis, personalized treatment strategies, and targeted postoperative care. Comprehensive pre- and postoperative planning is essential to optimize both visual function and long-term ocular surface integrity, ultimately ensuring a balance between oncologic control with functional and aesthetic preservation. Full article
(This article belongs to the Section Cancer Therapy)
Show Figures

Figure 1

23 pages, 1237 KiB  
Review
Review of Adoptive Cellular Therapies for the Treatment of Sarcoma
by James J. Fradin and John A. Charlson
Cancers 2025, 17(8), 1302; https://doi.org/10.3390/cancers17081302 - 12 Apr 2025
Viewed by 1055
Abstract
Sarcomas are a heterogeneous group of malignancies with limited therapeutic options, particularly in the metastatic setting. Adoptive cellular therapies (ACTs), including tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor (CAR) T-cell therapy, and T-cell receptor (TCR) gene-modified T-cell therapy, offer promising novel approaches for [...] Read more.
Sarcomas are a heterogeneous group of malignancies with limited therapeutic options, particularly in the metastatic setting. Adoptive cellular therapies (ACTs), including tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor (CAR) T-cell therapy, and T-cell receptor (TCR) gene-modified T-cell therapy, offer promising novel approaches for these refractory tumors. TIL-based therapy has demonstrated early efficacy in melanoma and myeloma, with ongoing trials exploring its role in sarcoma. CAR T-cell strategies targeting HER2, GD2, and B7-H3 antigens are in development, though challenges such as tumor microenvironment-mediated resistance and antigen escape remain significant. Engineered TCRs, particularly those targeting MAGE-A4 and NY-ESO-1, have shown promising clinical results in synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCLS), leading to the recent FDA approval of afamitresgene autoleucel (afami-cel) and letetresgene autoleucel (lete-cel). Despite encouraging preliminary data, ACT implementation faces barriers including limited antigen specificity, off-tumor toxicity, immune evasion, and manufacturing scalability. Future research will focus on optimizing lymphodepleting regimens, mitigating toxicity, enhancing in vivo persistence, and combining ACT with other therapeutic agents. As clinical trials expand, ACT holds the potential to revolutionize sarcoma treatment by offering durable, targeted therapies for previously refractory disease. Full article
(This article belongs to the Special Issue Sarcoma: Clinical Trials and Management)
Show Figures

Figure 1

11 pages, 5246 KiB  
Case Report
Congenital Melanocytic Nevus with Neurocristic Cutaneous Hamartoma: A Case Report
by Dina El-Rayes, Katlin Wilson, Sheilagh Maguiness, Daniel Miller, Gerardo Cazzato and Alessio Giubellino
Dermatopathology 2025, 12(2), 12; https://doi.org/10.3390/dermatopathology12020012 - 10 Apr 2025
Viewed by 1282
Abstract
Congenital melanocytic nevi (CMN) are benign tumors present at birth or arising in the first few months of life. A small subset of these nevi present with mild atypical features and heterogeneous differentiation, including Schwannian differentiation. We present a case of a 3-week-old [...] Read more.
Congenital melanocytic nevi (CMN) are benign tumors present at birth or arising in the first few months of life. A small subset of these nevi present with mild atypical features and heterogeneous differentiation, including Schwannian differentiation. We present a case of a 3-week-old with a 7 cm red/purple scalp nodule consistent with CMN with mild atypical heterogeneous areas. On histology, there were dermal nests of spindle cells in a fibrillar matrix, with increased vessels and clusters of small round melanocytes interspersed between collagen bundles and around adnexal structures. The lesion also exhibited rare pagetoid ascent of melanocytes as single cells and nests. Overall, these features were consistent with a CMN with nodular proliferative neurocristic cutaneous hamartoma (NCH) with a component of a compound mild atypical melanocytic proliferation. Next generation sequencing (NGS) identified a novel SH2B1::BRAF fusion. This case highlights the diagnostic challenges of heterogeneous differentiation within CMN in young children. Full article
Show Figures

Figure 1

41 pages, 2291 KiB  
Review
Understanding Merkel Cell Carcinoma: Pathogenic Signaling, Extracellular Matrix Dynamics, and Novel Treatment Approaches
by Maria Konstantaraki, Aikaterini Berdiaki, Monica Neagu, Sabina Zurac, Konstantinos Krasagakis and Dragana Nikitovic
Cancers 2025, 17(7), 1212; https://doi.org/10.3390/cancers17071212 - 2 Apr 2025
Viewed by 2613
Abstract
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer, driven by either Merkel cell polyomavirus (MCPyV) integration or ultraviolet (UV)-induced mutations. In MCPyV-positive tumors, viral T antigens inactivate tumor suppressors pRb and p53, while virus-negative MCCs harbor UV-induced mutations that [...] Read more.
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer, driven by either Merkel cell polyomavirus (MCPyV) integration or ultraviolet (UV)-induced mutations. In MCPyV-positive tumors, viral T antigens inactivate tumor suppressors pRb and p53, while virus-negative MCCs harbor UV-induced mutations that activate similar oncogenic pathways. Key signaling cascades, including PI3K/AKT/mTOR and MAPK, support tumor proliferation, survival, and resistance to apoptosis. Histologically, MCC consists of small round blue cells with neuroendocrine features, high mitotic rate, and necrosis. The tumor microenvironment (TME) plays a central role in disease progression and immune escape. It comprises a mix of tumor-associated macrophages, regulatory and cytotoxic T cells, and elevated expression of immune checkpoint molecules such as PD-L1, contributing to an immunosuppressive niche. The extracellular matrix (ECM) within the TME is rich in proteoglycans, collagens, and matrix metalloproteinases (MMPs), facilitating tumor cell adhesion, invasion, and interaction with stromal and immune cells. ECM remodeling and integrin-mediated signaling further promote immune evasion and therapy resistance. Although immune checkpoint inhibitors targeting PD-1/PD-L1 have shown promise in treating MCC, resistance remains a major hurdle. Therapeutic strategies that concurrently target the TME—through inhibition of ECM components, MMPs, or integrin signaling—may enhance immune responses and improve clinical outcomes. Full article
(This article belongs to the Special Issue Insights from the Editorial Board Member)
Show Figures

Figure 1

11 pages, 3911 KiB  
Article
AMPK Knockout Impairs the Formation of Three-Dimensional Spheroids
by Yea-In Park, Rackhyun Park, Siyun Lee, Chunghyeon Lee, Inkyu Yoo, Hakhyun Ka, Yang Hoon Huh, Jongkwang Hong and Junsoo Park
Life 2025, 15(4), 525; https://doi.org/10.3390/life15040525 - 22 Mar 2025
Viewed by 491
Abstract
AMP-activated protein kinase (AMPK) is an important regulator of cellular energy homeostasis, and AMPK contributes to cell growth, apoptosis, and autophagy. Although most cell studies have been performed using two-dimensional (2D) cell culture, recent studies have demonstrated that the three-dimensional (3D) spheroid technique [...] Read more.
AMP-activated protein kinase (AMPK) is an important regulator of cellular energy homeostasis, and AMPK contributes to cell growth, apoptosis, and autophagy. Although most cell studies have been performed using two-dimensional (2D) cell culture, recent studies have demonstrated that the three-dimensional (3D) spheroid technique is helpful in various cell research fields, such as tumor biology, due to its resemblance to the 3D tissue structure. However, the role of AMPK in 3D spheroid formation has not been characterized clearly. This study used the AMPK knockout cell line to examine the role of AMPK in 3D spheroid formation and is the first report describing the generation of 3D spheroids using AMPK knockout cells. While control cells produced round spheroids with a similar length-to-width ratio, AMPK knockout produced an oval shape with a more significant length-to-width ratio. We demonstrate that AMPK knockout spheroids contain significantly more prominent lysosomes in each cell, indicating that autophagic flux is impaired in 3D spheroids. Finally, flow cytometry analysis showed that AMPK knockout spheroids contain more apoptotic cells than control cells. These results indicate that AMPK is required for efficient 3D spheroid formation. Full article
(This article belongs to the Section Physiology and Pathology)
Show Figures

Figure 1

Back to TopTop